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Abstract Migraine is a common and frequently disabling
condition. Nevertheless, many migraine sufferers do not
consult for migraine, are not medically followed up and
self-treat the attacks. ‘‘Tour de France of migraine’’ con-
sisted of free-access conferences held in six large towns in
France following a wide public information campaign. This
sensitization campaign aimed at providing participants
with educational information on migraine disease and on
current therapies. Headache sufferers were then invited to
respond to two consecutive questionnaires delivered at the
end of the conferences and 3 months later to assess the
influence of the information delivered on their migraine
management. Tour de France of migraine recruited mainly
severe migraine sufferers, most of whom had already
consulted and were medically followed up. However,
migraine management was often suboptimal in these sub-
jects since most of them found their acute treatment of
attacks ineffective and only few of them received a pro-
phylactic treatment. Three months after the conferences,
more than half of respondents had consulted for headaches.
There was a significant improvement in migraine-related
disability, as reflected by a significant decrease in mean
Headache Impact Test 6-item score, which might have
been related to the higher proportion of subjects receiving a
prophylactic treatment of migraine. The Tour de France of
migraine campaign revealed the difficulty in sensitizing
migraine sufferers towards the necessity of being medically
followed up. Mainly patients with severe migraine attended
the conferences and derived clinical benefit from the edu-
cational program. Other strategies should be developed to
reach a wider population of migraine sufferers.
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Introduction
Migraine is a frequent condition affecting about 11% of
adult populations worldwide [1], yet many patients remain
undiagnosed or untreated. A nationwide population-based
epidemiologic survey carried out in France indicated that
60% of subjects diagnosed as having migraine are not
aware that they suffer from this disease [2]. Moreover,
although migraine is associated with high levels of dis-
ability and impairment of health-related quality of life,
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many migraine sufferers (50–80%) are not medically fol-
lowed up and self-treat their attacks [2–4]. The disability
associated with migraine is an important target for treat-
ment, and effective acute and preventative treatments exist,
but some of them are available by prescription only.
Importantly, the absence of medical control may promote
overuse of acute treatments, which may lead to medication-
overuse headache, a condition often refractory to treatment
[5].
Recently, the World Health Organization (WHO) in
collaboration with three international associations (World
Headache Alliance, International Headache Society,
European Headache Federation) initiated ‘‘Lifting the
burden’’, a global campaign to reduce the burden of
headache worldwide [6]. The campaign central tenet is that
the healthcare solution for headache in most areas of the
world is education. Educational programs directed towards
the general public and patients consulting general practi-
tioners, aiming to raise awareness of headache disorders
and their consequences are considered essential for the
diagnosis and management of migraine and other headache
disorders. Studies carried out in the setting of a health
maintenance organization or specialized headache clinic
indeed showed that addition of therapeutic patient educa-
tion to routine medical management improves the outcome
of migraine or tension-type headaches [7, 8]. Reinforce-
ment of information of the general population may also
improve migraine diagnosis and management for those
subjects who are not aware of their disease or not medically
followed up.
In this context, a series of conferences on migraine was
organized in several towns of France (‘‘Tour de France of
migraine’’) by the French Society for the Study of Migraine
and Headache (SFEMC) to sensitize the general public
towards migraine. These conferences targeted migraine
sufferers as well as their close relations and aimed at
providing information about migraine disease and the
possibilities of current proper management of migraine.
Headache sufferers were invited to respond to two con-
secutive questionnaires: the first one to establish their
headache characteristics as they attended the conference,
the second one 3 months later to assess the influence of the
conference on the management of their headaches. Results
from this study are presented below.
Patients and methods
Educational program
The sensitization campaign on migraine was initiated by
the SFEMC in association with the French Association of
Private Neurologists (ANLLF). It was conducted from
September to October 2007 in six towns of France: Lyon,
Rouen, Lille, Marseille, Toulouse and Paris (‘‘Tour de
France of migraine’’). The conferences intended for the
general public took place on a Saturday morning and were
free of registration fees. Each conference consisted of four
seminars delivered by migraine specialists and dealing with
definition, epidemiology, treatment and management of
migraine, with a particular focus on the relationship
between migraine and female hormones. The seminars
were given with the help of visual aids which were elab-
orated by the SFEMC and the same for all towns. Seminars
were then followed by debates. Information for attending
the conferences was circulated via local media, via the
SFEMC website and by means of public notices within
2 weeks beforehand.
Study questionnaires
The initial self-administered paper questionnaire was han-
ded out at the end of the conference. It was especially
intended for the individuals who said that they suffered
from headaches. Three months later, all respondents to the
first questionnaire who had provided their particulars and
given their consent were contacted by phone by the polling
institute TNS Healthcare and asked to respond to a second
simplified questionnaire.
The initial 24-item study questionnaire queried about—
(1) the reason why the subject attended the conference:
because he/she or someone amongst his/her close relations
was suffering from headaches, or only because he/she was
interested in health information; (2) subjects’ demograph-
ics: age, sex; (3) attributes of headaches: persistent or
recurrent quality, number of days per month, existence of
aura symptoms before the attacks; (4) migraine diagnostic
criteria for migraine without aura according to the Inter-
national Classification of Headache Disorders, 2nd edition
(ICHD-II), category 1.1 [9]; (5) headache-related disability
as evaluated by the Headache Impact Test 6-item (HIT-6)
assessing the impact of headaches on daily living activities
[10]; (6) whether the subject had already consulted spe-
cifically for headaches, and if yes, which practitioner; and
whether the subject was medically followed up for head-
aches; (7) the consumption of acute treatments of attacks,
the name and dosage of the medication most frequently
used as first-line treatment regardless of it was a non-pre-
scription- or a prescription-only medication; (8) whether
the subject took a preventive medication for migraine; and
(9) whether the subject intended to consult for headaches
after having attended the conference.
The medications used for the acute treatment of
migraine were classified as recommended (triptans, ergot-
amine derivatives, non-steroidal anti-inflammatory drugs,
aspirin alone or combined with metoclopramide) or non-
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recommended treatments (paracetamol, opioids) according
to the French National Authority for Health (HAS) rec-
ommendations, while specific treatment included triptans,
ergotamine derivatives and aspirin combined with meto-
clopramide [11]. Effectiveness of the usual treatment of
attacks was assessed according to the set of four questions
designed by the SFEMC and the HAS. This questionnaire
captures information about: (1) significant migraine relief
2 h after drug intake, (2) treatment tolerability, (3) single
drug intake to treat an attack and (4) rapid resumption of
normal social, family or professional activities. ‘‘Yes’’
responses to all four questions characterized treatment
effectiveness [11, 12].
The second 16-item study questionnaire, administered
by telephone, mainly consisted of the sections 5 and 7 of
the initial questionnaire. In addition, the second question-
naire queried about whether the subject had consulted for
headaches since the conference, and if yes, which practi-
tioner was consulted.
Ethical approval
Nominative data were recorded and subjects’ written
informed consent was required to participate in the second
phase of the survey. Therefore, study protocol was sub-
mitted to and approved by the French Commission on Data
Processing and Liberties (CNIL). Participants received no
compensation.
Data processing and statistical analysis
Responses to both questionnaires were processed by the
polling institute TNS Healthcare Sofres. Categorical variables
were summarized by the percentages in the corresponding
categories. Numerical variables were summarized by the
usual descriptive statistics (mean, SD). Statistical compari-
sons of data between subsets of subjects (e.g. subjects with or
without medical follow-up, initial vs. second questionnaire)
were performed using the Z test. Statistical significance was
considered at P \ 0.05.
Results
Survey population
A total of 143 questionnaires were collected during the
sensitization campaign (Phase 1 of the survey) including
one blank questionnaire. One hundred and twenty respon-
dents gave their particulars to be contacted by phone
3 months after the conference (Phase 2 of the survey). Of
them, 105 could be actually contacted and accepted to
respond to the second questionnaire. The remaining 15
subjects gave false particulars or did not respond to phone
call (n = 6), refused to participate to the second phase of
the survey (n = 5) or stated that they were not migraine
sufferers (n = 4).
Phase 1 of the survey: characteristics of the subjects
participating in the sensitization campaign
The population of individuals attending the conferences
was mainly made up of women (74%) and of headache
sufferers (80%). Most participants (95%) mentioned that
suffering from headaches was the main reason for attend-
ing the conference. Amongst the 114 participants who
stated that they suffered headaches, 110 (96%) were true
migraine sufferers according to the ICHD-II diagnostic
criteria, with a marked preponderance of subjects with
strict migraine (77 subjects, 70%) (code 1.1) over those
with probable migraine (code 1.6). Most migraine sufferers
were women (79%) and the majority (64%) had migraine
without aura. On average, the number of days per month
with headaches was 7.3 ± 6.8 (range 1–31), with 18% of
subjects having chronic daily headaches ([ 15 days/
month). The majority of migraine sufferers responding to
the initial questionnaire (70 subjects; 64%) were medically
followed up. Migraine sufferers with medical follow-up
comprised significantly more women (85 vs. 68%;
P \ 0.05) and fewer subjects aged 55–64 years (10 vs.
34%; P \ 0.01). Most migraine sufferers considered their
migraine as disabling, and 100/110 (95%) had a HIT-6
score above 55. Mean HIT-6 score was 66.9 ± 5.9 (range
49–76) and significantly higher for the migraine sufferers
who were medically follow-up (67.8 ± 5.5 vs. 65.2 ± 6.4
for those without medical follow-up; P \ 0.05). More
migraine sufferers with HIT-6 score [ 55 were medically
followed up (95 vs. 82% for those without medical follow-
up; P \ 0.05). Table 1 summarizes the data on migraine
management at the time of the conference for all migraine
sufferers participating in survey Phase 1. Nearly, all
migraine sufferers, either medically followed up or not, had
already consulted specifically for their headaches, mainly
general practitioners or neurologists. More migraine suf-
ferers with medical follow-up than without had consulted a
neurologist (P \ 0.05). Most migraine sufferers used to
treat their attacks, mainly with a recommended or a specific
treatment. Significantly more migraine sufferers with
than without medical follow-up used a recommended or
a specific treatment (both P \ 0.05) (Table 1). The mean
number of medication units (tablets, capsules, supposito-
ries, etc.) taken to treat an attack was 2.3 ± 2.0, with the
majority of migraine sufferers taking a single (49%) or two
medication units (26%). Only 11% of them took five or
more medication units, mainly those not medically fol-
lowed up (21 vs. 5% of those with medical follow-up;
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P \ 0.05). On the whole, the acute treatment of attacks was
found effective in only 40 of 93 migraine sufferers with
assessable responses at the SFEMC-HAS set of four
questions (43%). Only one-quarter of migraine sufferers
was currently taking a preventive medication for migraine,
mainly those medically followed up (P \ 0.05 vs. migraine
sufferers without medical follow-up). Of the migraine
sufferers not already medically followed up, two-thirds
intended to consult for migraine soon (Table 1).
Phase 2 of the survey: influence of the sensitization
campaign on migraine management
Of the 94 migraine sufferers participating in survey Phase
2, 49 (52%) consulted within the 3 months following the
conferences. Significantly more migraine sufferers previ-
ously medically followed up consulted compared with
those without medical follow-up (67 vs. 27%; P \ 0.05).
Most consulters consulted general practitioners (32 sub-
jects, 65%) and/or neurologists (19 subjects, 38%). One-
third of the non-consulters (34%) were migraine sufferers
who intended to consult at the end of the conferences. All
migraine sufferers with pronounced migraine-related dis-
ability at the time of the conferences (HIT-6 score [ 60)
had consulted. In the whole group of migraine sufferers
who completed the HIT-6 questionnaire at the end of
the conferences and 3 months later, mean HIT-6 score
decreased significantly from 66.9 ± 5.9 to 63.4 ± 8.3
(P \ 0.05). However, the observed decrease in mean
HIT-6 score was of a similar size whether migraine suf-
ferers had consulted or not (Fig. 1). The proportion of
migraine sufferers with HIT-6 score C 60 decreased from
100 to 86% (-14%) in those who consulted and from 83
to 58% (-25%) in those who did not. Regarding acute
treatments of attacks, no significant change was observed
between the two phases of the survey. Three months after
the conference, most migraine sufferers (93%) used med-
ications to treat the attacks, mainly specific and recom-
mended treatments (Fig. 2). Migraine sufferers medically
followed up still used more specific and recommended
treatments than those without medical follow-up. The mean
number of medication units taken to treat an attack
(2.3 ± 2.0 initially; 2.2 ± 2.6 3 months later) and the
proportion of migraine sufferers with effective treatment
Table 1 Migraine management for subjects responding to the initial questionnaire (Phase 1)
Characteristics of






followed upb, N = 39
Previous consultation for headaches 107 (97%) 70 (100%) 36 (93%)*
General practitioner 98 (91%)





Acute treatment of attacks 107 (97%)
Specific treatmenta 63 (59%) 50 (72%) 12 (32%)*
Non-specific treatmenta 39 (36%)
Recommended treatmenta 83 (77%) 61 (87%) 22 (56%)*
Non-recommended treatmenta 19 (18%)
Not specified 5 (5%)




Missing data 6 (5%)
Not applicable (already followed up) 70 (64%)
N indicates the number of migraine sufferers amongst the participants who responded to the initial questionnaire at the time of the conference
(Phase 1)
a According to the recommendations of the French National Authority for Health (HAS) for migraine medical management (adapted from Ref.
[11])
b Only the characteristics showing statistically significant differences (*P \ 0.05 vs. migraine sufferers medically followed up) between the two
subsets of migraine sufferers are shown in these columns
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did not differ significantly between the two phases of the
survey (Fig. 2). In contrast, 3 months after the conferences,
the proportion of migraine sufferers taking a preventive
medication for migraine was significantly larger than ini-
tially (P \ 0.05; Fig. 2).
Discussion
Although migraine is a frequent disease associated with
considerable disability, it remains largely unrecognized and
improperly treated. The objective of Tour de France of
migraine was to sensitize migraine sufferers and their close
relations to the necessity of seeking the care of a physician
to benefit from the current most effective therapies and
avoid the risk of medication overuse. Despite a large
information campaign, only a low proportion of headache
sufferers attended the conferences and it appears that most
of those who did generally had a more severe disease were
already medically followed up. Furthermore, the influence
of the information delivered on migraine sufferers’
behaviour and migraine management 3 months after the
conferences seems to have been rather limited.
Migraine (strict or probable) affects more than one in
five subjects in France (21%) [13]. The conferences orga-
nized in six important towns in France only recruited 142
headache sufferers that accepted to participate in the
survey, of whom 110 were recognized as true migraine
sufferers. This low rate of participation conforms well to
the notion that migraine sufferers show defeatism and
resignation towards medical care of their disease and their
willingness to manage their headaches by themselves [14]:
a preceding survey indicated that 28% of migraine suffer-
ers in France never consulted for migraine and 41% lapsed
consulting [4]. Insufficient patient information, as reflected
by the high proportion of migraine sufferers not self-aware
that they have migraine [2], may be the cause of their
unwillingness to seek medical care. Other factors may
include the fact that migraine attacks are relatively short
and rarely observed by the physicians, to whom they are
described retrospectively and succinctly or even not
reported at all, while the patients continue their own way to
manage the attacks with the notion that only themselves
have a good knowledge of their attacks. They would
eventually consult a physician only to get a prescription,
which would entail the risk of altering the normal patient–
physician relationship [15].
The population who actually attended such conferences
was mainly composed of headache sufferers (80% of
subjects), most of them (96% of headache sufferers) being
true migraine sufferers as defined by the ICHD-II diag-
nostic criteria for migraine. Moreover, the population of
migraine sufferers recruited via this campaign consisted
mainly of severe migraine sufferers, as attested by the HIT-
6 score: most migraine sufferers had a HIT-6 score [ 55
(range 49–76). The severity of the disease may explain the
moderate impact of this campaign.
Similar observations were made in a sensitization
campaign (Casilino study) on unrecognized migraine that
was conducted in Italy in 2003 [16]. Headache sufferers
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All migraine sufferers 
Fig. 1 Headache Impact Test 6-item scores at end of conferences
(white bars) and 3 months later (black bars) in the whole group of
migraine sufferers and according to medical consultation 3 months
later. Open triangle denotes difference between the mean HIT-6
scores recorded at the end of conferences and 3 months later.
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Fig. 2 Use of acute and
preventive treatments of
migraine at end of conferences
(white bars) and 3 months later
(black bars) in the whole group
of migraine sufferers. *P \ 0.05
versus end of conferences
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were recruited by a mailing to more than 8,000 households
listed in the registries of a group of ten general practitioners
and posters in the physicians’ waiting rooms. Migraine
sufferers were first identified by the ID Migraine screening
test [17], then migraine was diagnosed according to the
ICHD-II criteria during a consultation. The authors
expected to recruit 1,300–1,500 migraine sufferers via the
personal mails addressed: in reality, only 195 headache
sufferers consulted as a result of the sensitization cam-
paign. Most participants (92%) were migraine sufferers and
73% were diagnosed for the first time. As in Tour de
France of migraine, the migraine sufferers who actually
consulted were those with severe headaches: mean HIT-6
score was 61.5 ± 7.6 and subjects suffered a mean number
of 8.4 ± 9.0 days of headache per month with a mean pain
intensity of 8.6 ± 1.5 on a scale of 0–10. Like ours, this
sensitization campaign failed to bring a wide range of
undiagnosed headache sufferers into medical care: patients
with high-grade disability suffer migraine attacks of severe
intensity and use multiple drug units to treat the attacks
[14]. As underlined by the authors of the Casilino study,
more widespread use of rapid identification of potential
migraine sufferers by the ID Migraine test might be very
useful for a large recruitment of migraine patients to
medical care. Interestingly, 92% of patients identified using
ID Migraine in the Casilino study were true migraine
sufferers, versus 96% of headache sufferers attending the
conferences in the Tour de France of migraine, indicating
that a wide public information campaign mostly reaches
migraine sufferers and less subjects with other categories
of common headache disorders such as tension-type
headaches.
As expected, migraine sufferers not medically followed
up used fewer specific and recommended treatments of
migraine, more frequently took large number of medication
units for an attack, and fewer received a preventive treat-
ment of migraine. The conferences did not seem to have
influenced the therapeutic behaviour of the migraine suf-
ferers. This is in keeping with data from a pharmaceutical
campaign conducted in Denmark targeting the inappropri-
ate use of triptans which showed that intensive information
of pharmacy staff had no significant impact after 6 or
9 months on the patients’ consumption of triptans [18].
Nonetheless, 3 months after the conferences, more
migraine sufferers than initially received a preventive
treatment of migraine (34 vs. 25%), as a possible result of
the 27% of initially migraine sufferers without medical
follow-up who consulted after the conferences or of spe-
cific request from consulting migraine sufferers after the
sensitization campaign. Concomitantly, mean migraine
impact on daily life as assessed by the HIT-6 score
decreased slightly but significantly (-3.5; P \ 0.05) dur-
ing the period in the whole group of migraine sufferers.
There was no significant difference in impact change fol-
lowing the sensitization campaign whether migraine suf-
ferers had consulted or not, however, which makes difficult
the identification of the cause of migraine impact
alleviation.
The Tour de France of migraine sensitization campaign
has some limitations, however. It concerned mainly the
urban population of France, as it was conducted in only
six large towns in France. However, the prevalence of
migraine does not appear to differ according to community
size [13]. The proportion of responding subjects was quite
low and probably not totally representative of the whole
population of migraine sufferers since most participants
were severe migraine sufferers and already enrolled in the
healthcare system. On the other hand, a strength of the
survey is the relatively high proportion of migraine suf-
ferers (85%) that could be contacted again 3 months after
the sensitization campaign, with no apparent bias due to
population attrition. To extend this type of migraine sen-
sitization campaign, it may be interesting to develop other
ways of communication as the Internet, information close
to the pharmacists, etc.
In conclusion, the Tour de France of migraine campaign
that intended to sensitize headache sufferers to consult
mainly reached severe migraine sufferers who were already
medically followed up. Nevertheless, the sensitization
campaign had some positive influence on migraine man-
agement, in that some migraine sufferers previously with-
out medical follow-up actually consulted during the
3 months following the sensitization programme, more of
them received a preventive treatment, and a slight but
significant decrease in migraine impact on daily living was
observed. No relationship between these changes could be
firmly established, however. Other strategies should thus be
developed to reach a more general population of migraine
sufferers. Public information and individual patient’s
therapeutic education are indeed becoming an essential part
of the treatment of chronic diseases. It is now largely
recommended that the combination of both, complemen-
tary but not equivalent, should integrate the therapeutic
strategy of chronic diseases, such as asthma, diabetes and
migraine [6, 19, 20]. This strategy would be particularly
important for migraine, a condition where patient defeat-
ism and unawareness of the current effective treatments of
migraine might be at least in part responsible for the high
rate of exclusion from medical care.
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